Chris Peritore-Galve
banner
fcperitore.bsky.social
Chris Peritore-Galve
@fcperitore.bsky.social
Postdoc in the Borden Lacy Lab at Vanderbilt University Medical Center | Incoming Assistant Professor at The Ohio State University | Professional 🦠and 💩 aficionado | Non-professional 🪴🐶🐦 enthusiast| 🇲🇽 🇺🇸 |
15/20 The lack of outward signs of disease and limited histopathology was curious, so we tested this with additional TcdB3+ strains and found that the mild disease with edema + inflammation being the most informative markers was consistent across ribotype 017 strains.
November 7, 2025 at 7:11 PM
14/20 Mice infected with the TcdB3+ strain develop no appreciable epithelial damage, but they do exhibit high amounts of inflammation and edema. Surprisingly, even though AZD5148 did not neutralize TcdB3 in vitro, it significantly protected against the inflammation and edema phenotypes in vivo!
November 7, 2025 at 7:11 PM
11/20 What is baffling is that despite protecting against lethality and weight loss, mAb therapy did not have an impact on pathology. This could be due to systemic effects of neutralizing TcdB, or the prevention of further damage by directing more AZD5148 from the bloodstream to the tissue, or more.
November 7, 2025 at 7:11 PM